<scp>Antibody‐dependent cell‐mediated</scp> cytotoxicity using T cells with <scp>NK‐like</scp> phenotype in combination with avelumab, an <scp>anti‐PD‐L1</scp> antibody-Reference-Cited by-同舟云学术

Antibody‐dependent cell‐mediated cytotoxicity using T cells with NK‐like phenotype in combination with avelumab, an anti‐PD‐L1 antibody

Published:2022-08-15 Issue:2 Volume:167 Page:212-220
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Liu Dong¹,Hu Yuefeng²,Wei Jian²,Zhang Wen³,Piao Chunmei⁴,Lu Yongcheng⁵,Wang Yue⁶,Liu Jingwei⁶^ORCID,Lu Xu⁶

Affiliation:

1. Department of Radiology The First Hospital of Tsinghua University Beijing China

2. Department of Interventional Radiology Beijing Friendship Hospital, Capital Medical University Beijing China

3. Department of Oncology National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

4. Department of Oncology Beijing Anzhen Hospital Affiliated to the Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases Beijing China

5. Department of Pharmaceutical Sciences Bouvé College of Health Sciences, Northeastern University Boston Massachusetts USA

6. Department of Oncology Beijing Biohealthcare Biotechnology Co., Ltd Bejing China

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13530

Reference38 articles.

1. Cancer immunotherapy: the beginning of the end of cancer?

2. Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

3. Current advances in T-cell-based cancer immunotherapy

4. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

5. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy